Altered Expression of Brain Proteinase-Activated Receptor-2, Trypsin-2 and Serpin Proteinase Inhibitors in Parkinson’s Disease

详细信息    查看全文

• 作者：Michael J. Hurley ; Pascal F. Durrenberger…
• 关键词：Dyskinesia ; l ; DOPA ; Neuroinflammation ; Parkinson’s disease ; Proteinase ; activated receptor ; 2 ; Serpin (serine proteinase inhibitor clade A)
• 刊名：Journal of Molecular Neuroscience
• 出版年：2015
• 出版时间：September 2015
• 年：2015
• 卷：57
• 期：1
• 页码：48-62
• 全文大小：1,591 KB
• 参考文献：Afkhami-Goli A, Noorbakhsh F, Keller AJ, Vergnolle N, Westaway D, Jhamandas JH et al (2007) Proteinase-activated receptor-2 exerts protective and pathogenic cell type-specific effects in Alzheimer’s disease. J Immunol 179:5493-503CrossRef PubMed
  Alafuzoff I, Ince PG, Arzberger T, Al-Sarraj S, Bell J, Bodi I et al (2009) Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol 117:635-52CrossRef PubMed
  Aslam A, Buckley MG, Compton SJ, Wilson SJ, Howarth PH, Walls AF (2002) Allergen-induced upregulation of protease activated receptor 2 (PAR-2) expression in the bronchial epithelium of asthmatics. J Allergy Clin Immunol 109:A214CrossRef
  Barnum CJ, Tansey MG (2012) Neuroinflammation and non-motor symptoms: the dark passenger of Parkinson’s disease? Curr Neurol Neurosci Rep 12:350-58CrossRef PubMed
  Braak H, Del Tredici K, Rüb U et al (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197-11CrossRef PubMed
  Bushell T (2007) The emergence of proteinase-activated receptor-2 as a novel target for the treatment of inflammation-related CNS disorders. J Physiol 581:7-6PubMed Central CrossRef PubMed
  Durrenberger PF, Grunblatt E, Fernando FS, Monoranu CM, Evans J, Riederer P et al (2012) Inflammatory pathways in Parkinson’s disease; a BNE microarray study. Parkinson’s Dis 2012:214714
  German DC, Manaye KF, White CL 3rd et al (1992) Disease-specific patterns of locus coeruleus cell loss. Ann Neurol 32:667-76CrossRef PubMed
  Gunin AG, Kornilova NK, Vasilieva OV, Petrov VV (2011) Age-related changes in proliferation, the numbers of mast cells, eosinophils, and cd45-positive cells in human dermis. J Gerontol 66:385-92CrossRef
  Han MH, Hwang SI, Roy DB, Lundgren DH, Price JV, Ousman SS et al (2008) Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 451:1076-081CrossRef PubMed
  Hastings GA, Coleman TA, Haudenschild CC, Stefansson S, Smith EP, Barthlow R et al (1997) Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons. Implications for the regulation of motor learning and neuronal survival. J Biol Chem 272:33062-3067CrossRef PubMed
  Hoffman KB, Martinez J, Lynch G (1998) Proteolysis of cell adhesion molecules by serine proteases: a role in long term potentiation? Brain Res 811:29-3CrossRef PubMed
  Huntington JA (2011) Serpin structure, function and dysfunction. J Thromb Haemost 9(Suppl 1):26-4CrossRef PubMed
  Hurley MJ, Brandon B, Gentleman SM, Dexter DT (2013) Parkinson’s disease is associated with altered expression of CaV1 channels and calcium-binding proteins. Brain 136:2077-097CrossRef PubMed
  Janciauskiene S, Wright HT (1998) Inflammation, antichymotrypsin, and lipid metabolism: autogenic etiology of Alzheimer’s disease. BioEssays 20:1039-046CrossRef PubMed
  Jenner P (2008) Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 9:665-77CrossRef PubMed
  Kettenmann H, Hanisch UK, Noda M, Verkhratsky A (2011) Physiology of microglia. Physiol Rev 91:461-53CrossRef PubMed
  Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A (2013) The current and projected economic burden of Parkinson’s disease in the United States. Mov Disord 28:311-18CrossRef PubMed
  Lees AJ, Hardy J, Revesz T (2009) Parkinson’s disease. Lancet 373:2055-066CrossRef PubMed
  Liu P, Sun L, Zhao XL, Zhang P, Zhao XM, Zhang J (2014) PAR2-mediated epigenetic upregulation of alpha-synuclein contributes to the pathogenesis of Parkinson’s disease. Brain Res 1565:82-9CrossRef PubMed
  Lohman RJ, O’Brien TJ, Cocks TM (2008) Protease-activated receptor-2 regulates trypsin expression in the brain and protects against seizures and epileptogenesis. Neurobiol Dis 30:84-3CrossRef PubMed
  McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38:1285-291CrossRef PubMed
  Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET et al (2001) The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signalling. Nat Med 7:59-4CrossRef PubMed
  Noorbakhsh F, Vergnolle N, McArthur JC, Silva C, Vodjgani M, Andrade-Gordon P et al (2005) Proteinase-activated receptor-2 induction by neuroinflammation prevents neuronal death during HIV infection. J Immunol 174:7320-329CrossRef PubMed
  Noorbakhsh F, Tsutsui S, Vergnolle N, Boven LA, Shariat N, Vodjgani M et al (2006) Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J Exp Med 203:425-35PubMed Central CrossRef PubMed
  Paulus W, Jellinger K (1991) The neuropathologic basis of different clinical subgroups of Parkinson’s disease. J Neuropathol Exp Neurol 50:743-55CrossRef PubMed
  Qian Z, Gilber
• 作者单位：Michael J. Hurley (1)
  Pascal F. Durrenberger (1)
  Steve M. Gentleman (2)
  Andrew F. Walls (3)
  David T. Dexter (1)
  
  1. Centre for Neuroinflammation and Neurodegeneration, Division of Brain Sciences, Department of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, London, W12 0NN, UK
  2. Neuropathology Unit, Division of Brain Sciences, Department of Medicine, Imperial College London, Charing Cross Campus, St Dunstan’s Road, London, W6 8RP, UK
  3. Immunopharmacology Group, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK
  
• 刊物主题：Neurosciences; Neurochemistry; Cell Biology; Proteomics; Neurology;
• 出版者：Springer US
• ISSN：1559-1166

文摘

Neuroinflammation is thought to contribute to cell death in neurodegenerative disorders, but the factors involved in the inflammatory process are not completely understood. Proteinase-activated receptor-2 (PAR2) expression in brain is increased in Alzheimer’s disease and multiple sclerosis, but the status of PAR2 in Parkinson’s disease is unknown. This study examined expression of PAR2 and endogenous proteinase activators (trypsin-2, mast cell tryptase) and proteinase inhibitors (serpin-A5, serpin-A13) in areas vulnerable and resistant to neurodegeneration in Parkinson’s disease at different Braak α-synuclein stages of the disease in post-mortem brain. In normal aged brain, expression of PAR-2, trypsin-2, and serpin-A5 and serpin-A13 was found in neurons and microglia, and alterations in the amount of immunoreactivity for these proteins were found in some brain regions. Namely, there was a decrease in neurons positive for serpin-A5 in the dorsal motor nucleus, and serpin-A13 expression was reduced in the locus coeruleus and primary motor cortex, while expression of PAR2, trypsin-2 and both serpins was reduced in neurons within the substantia nigra. There was an increased number of microglia that expressed serpin-A5 in the dorsal motor nucleus of vagus and elevated numbers of microglia that expressed serpin-A13 in the substantia nigra of late Parkinson’s disease cases. The number of microglia that expressed trypsin-2 increased in primary motor cortex of incidental Lewy body disease cases. Analysis of Parkinson’s disease cases alone indicated that serpin-A5 and serpin-A13, and trypsin-2 expression in midbrain and cerebral cortex was different in cases with a high incidence of l-DOPA-induced dyskinesia and psychosis compared to those with low levels of these treatment-induced side effects. This study showed that there was altered expression in brain of PAR2 and some proteins that can control its function in Parkinson’s disease. Given the role of PAR2 in neuroinflammation, drugs that mitigate these changes may be neuroprotective when administered to patients with Parkinson’s disease. Keywords Dyskinesia l-DOPA Neuroinflammation Parkinson’s disease Proteinase-activated receptor-2 Serpin (serine proteinase inhibitor clade A)